Adalta Ltd. · ASX:1AD
Adalta — Investor Presentation (January 2017)
26 slides from Adalta's investor presentation, Jan 17, 2017
Slide 1: i-bodies – a new class of protein therapeutics to treat human disease
For personal use only i-bodies – a new class of protein therapeutics to treat human disease January 2017 Sam Cobb, CEO and Managing Director AdAlta Limited (ASX:1AD) [email protected]
Slide 2: Disclaimer
Disclaimer For personal use only Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. This presentation is not an offer or in
Slide 3: Corporate and investment summary
Corporate and investment summary A drug discovery and development company For personal use only Capital structure focused on using its proprietary technology ASX code 1AD platform to generate a new class of protein Shares on issue* 101,037,617 therapeutics, known as i-bodies, for treating a Share pr
Slide 4: i-body technology
i-body technology Long loop that enables access to For personal use only AdAlta is developing a new technology platform that produces novel drug targets unique proteins known as i-bodies, that mimic the shape of shark antibody binding domain and engineers their key stability features into a human pr
Slide 5: Fibrosis: unmet medical need with multiple indications
Fibrosis: unmet medical need with multiple indications For personal use only Developing i-bodies as improved therapies for the treatment of fibrosis – a condition that is prevalent in 45-50% of all diseases Fibrosis can occur in many tissues of the body Lung Eye Liver as a result of inflammation or
Slide 6: Lead program in Idiopathic Pulmonary Fibrosis (IPF)
AD-114 lead program in Idiopathic Pulmonary Fibrosis (IPF) For personal use only AD-114 is lead i-body candidate in pre-clinical development – Demonstrates both anti-fibrotic and anti-inflammatory activity in the lung – Important for arresting and modifying the disease and tackling the treatment of
Slide 7: CXCR4 and idiopathic pulmonary fibrosis (IPF)
CXCR4 and idiopathic pulmonary fibrosis (IPF) For personal use only CXCR4 expression increased in fast progressing IPF patient tissue 590 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 179 2009 Patients that included. rapidly Diagnosis of IPF was progress based on guidelinesexpress o
Slide 8: AD-114 binds to lung tissue from patients with fibrosis
AD-114 binds to lung tissue from patients with fibrosis For personal use only AD-114 was used for Immunohistochemical (IHC) staining of normal and diseased lung tissues to verify expression of CXCR4 in situ AD-114 does not bind lung tissue from AD-114 binds to lung tissue from lungs normal lungs wit
Slide 9: AD-114 prevents lung fibrosis in disease models
AD-114 prevents lung fibrosis in disease models For personal use only Extensive pre-clinical AD-114 studies have demonstrated positive in vitro (in the lab) and in vivo (in animals) data Normal IPF lung tissue IPF lung tissue + AD-114 lung tissue (lung disease mouse model) dosed for 21 days (lung di
Slide 10: AD-114 prevents lung fibrosis in disease models
AD-114 prevents lung fibrosis in disease models For personal use only AD-114 significantly reduces Ashcroft scores in both prophylactic and therapeutic modes of the Bleomycin mouse model of fibrosis Ashcroft Score Prophylactic Mode Ashcroft Score Therapeutic Mode 8 8 6 Ashcroft score 6 Ashcroft Scor
Slide 11: Key advantages compared to existing IPF treatments
AD-114 key advantages compared to existing IPF treatments For personal use only AD-114 has greater in vitro efficacy compared to the only approved therapies Nintedanib and Pirfenidone for IPF No effect Effect on Human tissue treatment on normal diseased / In vitro activity tissue IPF tissue – Existi
Slide 12: Global market interest in fibrosis treatments
Global market interest in fibrosis treatments Recent transactions confirm that big pharma are actively acquiring fibrosis assets at For personal use only an early stage – typically based on Phase I results Date Company Target Acquired by Deal value (US$) Deal commentary Sep-15 Adheron SDP051 Roche $
Slide 13: AD-114 and non-alcoholic steatohepatitis (NASH)
AD-114 and non-alcoholic steatohepatitis (NASH) For personal use only Non-alcoholic steatohepatitis (NASH) is a pandemic, metabolic disease which has both inflammatory and fibrotic components AD-114 is lead i-body candidate in pre-clinical development – Demonstrates both anti-fibrotic and anti-infla
Slide 14: AD-114 prevents fibrosis in a mouse model of liver fibrosis
Normal Vehicle AD-114 prevents fibrosis in a mouse model of liver fibrosis Vehicleuse only ographs of HE-stained liver sections x50 x200 Therapeutic settingx50 x200 ID: 207 ID: 308 i-body For personal x200 x50 x200 x50 x200 Normal NASH liver tissue NASH liver tissue + AD-114 ID: 308 liver tissue (li
Slide 15: AD-114 prevents fibrosis in a mouse model of liver fibrosis
Figure 3. Biochemistry Figure 3.1. Serum ALT Figure 3.2. Liver AD-114 prevents fibrosis in a mouse model of liver fibrosis For personal use only AD-114 decreased serum ALT levels and non-alcoholic fatty liver diseaseFigure 4.2. NAFLD Activity score (NAFLD) score compared with the vehicle or disease
Slide 16: AD-114 and eye fibrosis
AD-114 and eye fibrosis For personal use only Infections or inflammation in the eye result in impairment of visual function and can ultimately lead to fibrosis. Complications from common eye diseases that can result in fibrosis occur in age related macular degeneration (AMD) and diabetic retinopathy
Slide 17: AD-114 prevents eye fibrosis
evaluated for collagen content using the Masson Trichrome Stain caused by laser induced retinal scarring (see Figure 3). In addition and at 21 AD-114 days post reduced geneadministration 150 expression of a number of fibrosis-related lesion size (u (which stains blue) and images are analysed as per
Slide 18: AD-114 reduces lesion size and number
AD-114 reduces lesion size and number AD-114 is able to reduce the number and size of the lesion in both preventative and For personal use only therapeutic models of CNV Eylea was also able to reduce lesion number and size in these models Retina lesion leakage number per eye Individual retina lesion
Slide 19: AD-114 reduces fibrosis
AD-114 reduces fibrosis For personal use only AD-114 is able to significantly reduce fibrosis as measured by trichrome staining in both Fibrosis vs Choroid Thickness Ratio preventative and therapeutic models of CNV 8 Eylea was also able to reduce fibrosis in these models 6 4 2 0 e l) l) l) cl m m m
Slide 20: AD-114 development: key milestones
AD-114 development: key milestones For personal use only CY2017 CY2018 Q1 Q2 Q3 Q4 Q1 Q2 Manufacturing Partnering of lead candidate Toxicology studies based on other benchmark deals Orphan designation Phase I Publication of data Other fibrosis indications BD and partnerships 20
Slide 21: Expected news flow next months
Expected news flow next 12 months For personal use only Q3 & Q4 2016 ü Commence manufacturing of material for toxicology testing with FujiFilm Diosynth Biotechnologies ü Additional AD-114 IPF fibrosis data ü Completion of evaluation of AD-114 with IPF clinicians Alfred Hospital ü Completion of AD-11
Slide 22: AdAlta business model – strategy to create value
AdAlta business model – strategy to create value For personal use only Pharma & biotech partnerships Revenues: Upfronts, i-body FTEs, milestones & royalties i-bodies new technology drug class platform and Potential in multiple library In-house disease indications Licence to pipeline of pharma drug R
Slide 23: Market benchmarks
Market benchmarks For personal use only Fibrosis lead AD-114 Sep-15 acquired by Roche Aug-15 acquired by BMS Nov-14 acquired by BMS $105m + $475m milestones $150m + $1.25b milestones $444m phase I asset phase IIa asset phase I asset Next gen antibodies April-16 with Abbvie Dec -15 with Roche Nov-15
Slide 24: Management and Board in place to deliver strategy
Management and Board in place to deliver strategy For personal use only Sam Cobb: Founding CEO and Director Dr John Chiplin: Independent Director Extensive experience in raising equity, contract and CEO of investment Company NewStar Ventures grant funding Managing Director of acquired antibody compa
Slide 25: Scientific Advisory Board
Scientific Advisory Board Internationally recognised with proven track record of drug development For personal use only David McGibney: pre-clinical and John Westwick: pulmonary drug clinical advisor discovery and development 20 years with Pfizer, including Head of Over 14 years experience at Novart
Slide 26: AdAlta investment summary
AdAlta investment summary For personal use only Powerful proprietary technology platform to develop a pipeline of i-bodies for the treatment of a wide range of human diseases Initial focus on treating Idiopathic Pulmonary Fibrosis and other fibrotic diseases - high unmet clinical need Advanced lead